Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
By Georgina V. Long, A. Menzies, A. Nagrial, L. Haydu, Anne L. Hamilton, G. Mann, T. M. Hughes, John F. Thompson, R. Scolyer, R. Kefford. Journal of Clinical Oncology, 2011
1,048 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/6ef6dc27b73db7ae38ca06762d5dd8dbdb837e61
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma (2011, result): “In addition, we note that the frequencies of V600E and V600K mutations in our cohort are similar to those reported in the Australian study of 197 patients with advanced melanoma.(21) The interpretation of the shorter survival among BRAF patients who did not receive BRAF orMEK inhibitors compared wit”
- KIT as a therapeutic target in metastatic melanoma. (2011, background): “Chronically sun-damaged 5 (18) Increased lactate dehydrogenasea 11 (39)”
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011, neutral): “Arthralgia Grade 2 60 (18) 1 (<1) Grade 3 11 (3) 2 (<1) Rash Grade 2 33 (10) 0 Grade 3 28 (8) 0 Fatigue Grade 2 38 (11) 33 (12) Grade 3 6 (2) 5 (2) Cutaneous squamous-cell carcinoma‡ Grade 3 40 (12) 1 (<1) Keratoacanthoma§ Grade 2 7 (2) 0 Grade 3 20 (6) 0 Nausea Grade 2 25 (7) 32 (11) Grade 3 4 (1) ”
- Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017, background): “Two major new classes of effective systemic therapeutic agents are now in widespread clinical use: immunotherapies (eg, checkpoint inhibitors against cytotoxic T lymphocyte antigen 4 [CTLA-4] and/or programmed death 1 [PD-1]), which enhance the natural host antitumor immune response; and molecularly”
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011, background): “Mutation of the BRAF gene is present in approximately 50% of cutaneousmelanomas and results in the constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, responsible for controlling cellular proliferation, apoptosis, and migration (4, 5).”